VIA
TAK icon

Vident Investment Advisory’s Takeda Pharmaceutical TAK Stock Holding History

Vident Investment Advisory’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-11,294
Closed -$178K – 935
2023
Q2 		$178K Buy
+11,294
New +$185K 0.01% 1078

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vident Investment Advisory's TAK Position: Q3 2023 in Review

Vident Investment Advisory sold out of Takeda Pharmaceutical (TAK) in Q3 2023, closing a stake of 11,294 shares — an estimated $178K sold.

Vident Investment Advisory first reported a position in TAK in Q2 2023 and held it in 1 quarter. The position peaked at $178K in Q2 2023. 312 funds tracked by Wall St. Rank hold TAK as of Q3 2023.

  • Vident Investment Advisory reported no remaining Takeda Pharmaceutical position as of Q3 2023 after selling out during the quarter.
  • Vident Investment Advisory sold 11,294 Takeda Pharmaceutical shares in Q3 2023, an estimated $178K.
  • Vident Investment Advisory first reported a position in Takeda Pharmaceutical in Q2 2023 and held it in 1 quarter.
  • Vident Investment Advisory's Takeda Pharmaceutical position peaked at $178K in Q2 2023.
  • 312 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2023.

Based on Vident Investment Advisory's 13F filing for Q3 2023.